BioSpace News Archive

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced Mayo Clinic has committed $1.75M as a lead investor in a $7 million convertible note financing round.

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that the Drug Master File (DMF) that its partner, Austrianova, filed with the U.S. Food and Drug Administration (FDA) has been accepted without any questions or suggested changes. The FDA’s Center

Rafarma Pharmaceuticals, Inc. OTC:(RAFA) presents the following letter to Rafarma shareholders from CEO Vladimir Dolgolenko: To Our Shareholders: During these exciting times I wanted to reach out to our shareholders and clarify some questions I have received. As recently announced, there will be a change in control forthcoming for Rafarma. The change in control will not affect the current share structure of the company. There has bee

- Government of Canada will support advancement of VBI’s coronavirus program through Phase 2 clinical development - Pre-clinical data are expected to enable selection of clinical candidates in Q3 2020 and the initiation of clinical studies by the end of 2020

Children’s Hospital of Philadelphia and MOREHealth, a global healthcare company, announced their new agreement that enables patients access to CHOP’s exceptional physicians through MOREHealth’s Physician Collaboration Platform™.

Animal Data has Potential Implications for Ongoing COVID-19 Prevention Study Company Continues Quest to Dominate Intellectual Property Regarding COVID-19 Associated Pathologies

Children’s National Hospital’s Pediatric study results mirror disparities found in adult populations across the U.S

Building on its more than 50-year commitment to women’s healthcare, today Bayer launched the We’re for Her initiative, which includes a partnership with the humanitarian organization Direct Relief that will help break down barriers so more women across the United States can access contraceptives and make

Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces the closing of its registered direct offering of American Depositary Shares on the NASDAQ Global Market.

AstraZeneca, a front-runner in the race for a COVID vaccine, recently announced that they would begin enrolling for their Phase II/III clinical trial in Mid-August.